First in vivo proof of concept of the impact of your compound designed to treat type 2 diabetes on cardiovascular complications and/or dyslipidemia, in terms of whole-body lipid homeostasis.
The Lipid tolerance test investigates how dyslipidemic animals treated with your compound regulate triglycerides and free fatty acids after lipid intake.
Key benefits
- Suitable for large-scale screening in vivo (20-30 compounds/week).
- Yielding in vivo insights into your compound's efficacy in treating cardiovascular complications and/or dyslipidemia associated with type 2 diabetes
- Sensitivity (15%) to detect a statistically significant impact of your compound on postprandial blood lipid regulation:
Species
- Rat
- Mouse
Add-on studies
- Hepatic VLDL-TG production test in the same animals (hepatic lipogenesis index)
- Fecal analysis to estimate the effect of your compound on intestinal lipid absorption in the same animals
- Glucose tolerance testing in the same animals
- Triglycerides / cholesterol absorption.
